Skip to content

Technological Development and Clinical Parallel Testing of PGT-G

Technological Development and Clinical Parallel Testing of Preimplantation Genetic Testing for Generalization

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05609708
Enrollment
55
Registered
2022-11-08
Start date
2022-12-12
Completion date
2025-11-01
Last updated
2024-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Genetic Disease

Keywords

PGT, stLFR-WGS

Brief summary

Preimplantation genetic testing (PGT) has three different testings according to the type of genetic disease, which was classified as PGT-M, PGT-SR and PGT-A. If the couple is tested for two different genetic diseases at the same time, it is necessary to customize the probe and adopt different detection methods, which increases the cost and cycle of testing. Advanced expert pre-experimental analysis is required for PGT-M in couples with monogenic disease. If the family members are unavailable, only the polar bodies, sperms or affected embryos can be used to analysis, which not only increases the risk of failure, but also increases the difficulty of detection. At present, BGI has developed a new single-tube complete Long fragment whole genome sequencing (stLFR-WGS) technology, which uses the same molecular tag on the short read sequencing fragments from the same long DNA molecule to achieve accurate short read sequencing to obtain long DNA information. Multiple genetic abnormalities such as gene variation, chromosome aneuploidy and chromosome structure rearrangement can be directly detected in embryos without pre-experiment of family members, so as to achieve universal normalization of the three PGT methods and solve the PGT detection needs of patients with multiple genetic diseases.

Interventions

None listed

Sponsors

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
20 Years to 45 Years

Inclusion criteria

1. Patients undergoing PGT cycle; 2. Patients with balanced chromosomal structural rearrangement (reciprocal translocation, Robertsonian translocation, inversion, etc.) by conventional karyotype analysis; 3. Clearly diagnosed monogenic genetic disease, and the related genes and their mutations are judged to be pathogenic or likely pathogenic; 4. Chromosomal abnormalities in recurrent abortion tissues or in PGT-A embryos; The number of blastocysts was \>= 1, and the morphological classification was more than 4BC/4CB.

Exclusion criteria

1. Belonged to any contraindications of PGT; 2. Failed to embryo biopsy; 3. Failed to embryo WGA failure or abnormal quality control; 4. Failed to embryo sequencing, and the result was unknown.

Design outcomes

Primary

MeasureTime frameDescription
diagnosis specificity1 day (the time of sequencing)specificity
diagnosis sensitivity1 day (the time of sequencing)sensitivity

Countries

China

Contacts

Primary ContactPing Yuan, PhD
kekeyp1983@163.com86-20-81332230
Backup ContactLiushan Ou
sys_iit@163.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026